Lapatinib (GW572016) is a drug with dual actions: it selectively inhibits both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Promising drug in treatment of breast cancer.
- ↑ Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer research 2006;66:1630-9. (Direct link – subscription may be required.)
- ↑ Tuma RS. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. Journal of the National Cancer Institute 2007;99:348-9. (Direct link – subscription may be required.)
- ↑ Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine 2006;355:2733-43. (Direct link – subscription may be required.)
This article is a work in progress. Please feel free to contribute to it.